PE20081238A1 - Piperidinas sustituidas como antagonistas de hdm2 - Google Patents
Piperidinas sustituidas como antagonistas de hdm2Info
- Publication number
- PE20081238A1 PE20081238A1 PE2007000844A PE2007000844A PE20081238A1 PE 20081238 A1 PE20081238 A1 PE 20081238A1 PE 2007000844 A PE2007000844 A PE 2007000844A PE 2007000844 A PE2007000844 A PE 2007000844A PE 20081238 A1 PE20081238 A1 PE 20081238A1
- Authority
- PE
- Peru
- Prior art keywords
- trifluoromethyl
- carbonyl
- heteroaryl
- substituted
- cyclyl
- Prior art date
Links
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 title abstract 4
- 102100032257 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title 1
- -1 4-TRIFLUORomethyl-PHENOXY Chemical class 0.000 abstract 3
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 abstract 2
- 101001043818 Mus musculus Interleukin-31 receptor subunit alpha Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical class C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE REFIERE A COMPUESTOS PIPERIDINAS SUSTITUIDAS DE FORMULA (I), EN DONDE R1 ES HETEROCICLICO, HETEROCICLENILO O HETEROARILO OPCIONALMENTE SUSTITUIDOS CON Z; A ES O, CR8R9, S, SO2, NR10 O CO; m ES 0-2; R2 ES ARILO, HETEROARILO, CICLILO, ENTRE OTROS; R3 ES ARILO, HETEROARILO, CICLILO, HETEROCICLILO, ENTRE OTROS; R4 O R4' SON INDEPENDIENTEMENTE H, ALQUILO, ALQUENILO, ENTRE OTROS O JUNTOS PUEDEN FORMAR UN ESPIROCICLILO, ESPIROHETEROCICLILO; R5, R5', R7 Y R7' SON INDEPENDIENTEMENTE H, ALQUILO, ALQUENILO, ENTRE OTROS; R6 O R6' SON NDEPENDIENTEMENTE, H, ALQUILO, ALQUENILO, ENTRE OTROS. SON SELECCIONADOS: (1,3,4,9-TETRAHIDRO-b-CARBONIL-2-IL)-[3-(4-TRIFLUOROMETIL-FENOXI)-1-(4-TRIFLUOROMETIL-PIRIDIN-3-CARBONIL)-PIPERIDIN-3-IL]-METANONA, [4-(2-METOXI-FENIL)-PIPERAZINI-1-IL]-[3-(4-TRIFLUOROMETIL-PIRIDIN-3-CARBONIL)-PIPERIDIN-3-IL]-METANONA, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA Y UN PROCEDIMIENTO DE PREPARACION. ESTOS COMPUESTOS SON INHIBIDORES DE LA PROTEINA HDM2 O MDM2 (DOUBLE MINUTE 2 HUMANA), SIENDO UTILES EN EL TRATAMIENTO DE CANCER, ENFEREMEDADES QUE IMPLICAN PROLIFERACION CELULAR ANORMAL O CAUSADAS POR NIVELES DE P53 INADECUADOS
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US81775306P | 2006-06-30 | 2006-06-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20081238A1 true PE20081238A1 (es) | 2008-09-04 |
Family
ID=38656615
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2007000844A PE20081238A1 (es) | 2006-06-30 | 2007-07-02 | Piperidinas sustituidas como antagonistas de hdm2 |
Country Status (17)
Country | Link |
---|---|
US (1) | US7884107B2 (es) |
EP (1) | EP2035416A1 (es) |
JP (1) | JP2009542666A (es) |
KR (1) | KR20090042779A (es) |
CN (1) | CN101595107A (es) |
AR (1) | AR061726A1 (es) |
AU (1) | AU2007269836A1 (es) |
BR (1) | BRPI0713119A2 (es) |
CA (1) | CA2656398A1 (es) |
CO (1) | CO6150158A2 (es) |
IL (1) | IL196152A0 (es) |
MX (1) | MX2009000285A (es) |
NO (1) | NO20090469L (es) |
PE (1) | PE20081238A1 (es) |
TW (1) | TW200808781A (es) |
WO (1) | WO2008005268A1 (es) |
ZA (1) | ZA200900204B (es) |
Families Citing this family (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8546404B2 (en) * | 2005-12-13 | 2013-10-01 | Merck Sharp & Dohme | Compounds that are ERK inhibitors |
US7807672B2 (en) * | 2006-02-16 | 2010-10-05 | Schering Corporation | Compounds that are ERK inhibitors |
CA2656393A1 (en) * | 2006-06-30 | 2008-01-10 | Schering Corporation | Method of using substituted piperidines that increase p53 activity |
US20080051380A1 (en) * | 2006-08-25 | 2008-02-28 | Auerbach Alan H | Methods and compositions for treating cancer |
US20080051375A1 (en) * | 2006-08-25 | 2008-02-28 | Auerbach Alan H | Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent, and compositions containing the same |
JP5649825B2 (ja) * | 2007-01-31 | 2015-01-07 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | 安定化させたp53ペプチドおよびその使用法 |
KR101525754B1 (ko) | 2007-03-28 | 2015-06-09 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 스티칭된 폴리펩티드 |
CA2690809A1 (en) | 2007-06-15 | 2008-12-24 | Microphage Incorporated | Method of detection of microorganisms with enhanced bacteriophage amplification |
WO2009009132A1 (en) * | 2007-07-12 | 2009-01-15 | Cougar Biotechnology, Inc. | Use of 17alpha-hydroxylase/c17, 20-lyase inhibitors for the treatment of cancer |
JP5562865B2 (ja) | 2007-12-17 | 2014-07-30 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Trpv1のイミダゾロ−、オキサゾロ−、及びチアゾロピリミジン・モジュレーター |
ES2556353T3 (es) * | 2008-02-21 | 2016-01-15 | Merck Sharp & Dohme Corp. | Compuestos que son inhibidores de las ERK |
EP3409762A1 (en) | 2008-03-17 | 2018-12-05 | The Scripps Research Institute | Combined chemical and genetic approaches for generation of induced pluripotent stem cells |
TW201011009A (en) * | 2008-09-15 | 2010-03-16 | Priaxon Ag | Novel pyrrolidin-2-ones |
RU2506257C2 (ru) * | 2008-09-18 | 2014-02-10 | Ф.Хоффманн-Ля Рош Аг | Замещенные пирролидин-2-карбоксамиды |
US8354444B2 (en) * | 2008-09-18 | 2013-01-15 | Hoffmann-La Roche Inc. | Substituted pyrrolidine-2-carboxamides |
CN102317442B (zh) | 2008-12-17 | 2014-08-13 | 斯克里普斯研究所 | 干细胞的产生和保持 |
US7928233B2 (en) | 2009-02-10 | 2011-04-19 | Hoffmann-La Roche Inc. | Spiroindolinone pyridine derivatives |
US8217051B2 (en) | 2009-02-17 | 2012-07-10 | Hoffmann-La Roche Inc. | Spiroindolinone derivatives |
US8076482B2 (en) | 2009-04-23 | 2011-12-13 | Hoffmann-La Roche Inc. | 3,3′-spiroindolinone derivatives |
US8017607B2 (en) | 2009-10-14 | 2011-09-13 | Hoffmann-La Roche Inc. | N-substituted-pyrrolidines as inhibitors of MDM2-P-53 interactions |
CN104945382B (zh) * | 2009-10-14 | 2020-02-07 | 默沙东公司 | 提高p53活性的取代的哌啶和其用途 |
CN102741394B (zh) | 2009-10-16 | 2016-05-04 | 斯克里普斯研究所 | 多能细胞的诱导 |
US8088815B2 (en) | 2009-12-02 | 2012-01-03 | Hoffman-La Roche Inc. | Spiroindolinone pyrrolidines |
US8288431B2 (en) | 2010-02-17 | 2012-10-16 | Hoffmann-La Roche Inc. | Substituted spiroindolinones |
WO2011123572A1 (en) | 2010-03-31 | 2011-10-06 | The Scripps Research Institute | Reprogramming cells |
US8217044B2 (en) | 2010-04-28 | 2012-07-10 | Hoffmann-La Roche Inc. | Spiroindolinone pyrrolidines |
JO2998B1 (ar) * | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
CN103003416B (zh) | 2010-06-15 | 2016-11-16 | 细胞动力学国际有限公司 | 从小体积的外周血产生诱导性多潜能干细胞 |
EP2601289B1 (en) | 2010-08-04 | 2017-07-12 | Cellular Dynamics International, Inc. | Reprogramming immortalized b cells |
CN108570097A (zh) | 2010-08-13 | 2018-09-25 | 爱勒让治疗公司 | 拟肽大环化合物 |
FR2967072B1 (fr) | 2010-11-05 | 2013-03-29 | Univ Dundee | Procede pour ameliorer la production de virus et semences vaccinales influenza |
MX2013006739A (es) * | 2010-12-16 | 2013-07-17 | Roche Glycart Ag | Terapia combinada de anticuerpo cd20 afucosilado con inhibidor de mdm2. |
US9732319B2 (en) | 2010-12-22 | 2017-08-15 | Fate Therapeutics, Inc. | Cell culture platform for single cell sorting and enhanced reprogramming of iPSCs |
WO2012172555A1 (en) | 2011-06-14 | 2012-12-20 | Yeda Research And Development Co. Ltd. | Combination therapy to prevent dcis formation and progression to breast cancer |
CA2841165A1 (en) | 2011-07-11 | 2013-01-17 | Cellular Dynamics International, Inc. | Methods for cell reprogramming and genome engineering |
JP6093770B2 (ja) | 2011-09-27 | 2017-03-08 | アムジエン・インコーポレーテツド | 癌の治療のためのmdm2阻害剤としての複素環化合物 |
MX358886B (es) | 2011-10-18 | 2018-08-31 | Aileron Therapeutics Inc | Macrociclos peptidomimeticos. |
WO2013062923A1 (en) * | 2011-10-28 | 2013-05-02 | Merck Sharp & Dohme Corp. | MACROCYCLES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF |
US9062071B2 (en) | 2011-12-21 | 2015-06-23 | Merck Sharp & Dohme Corp. | Substituted piperidines as HDM2 inhibitors |
SG11201404648PA (en) * | 2012-02-15 | 2014-09-26 | Aileron Therapeutics Inc | Peptidomimetic macrocycles |
US8987414B2 (en) | 2012-02-15 | 2015-03-24 | Aileron Therapeutics, Inc. | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles |
US20130245089A1 (en) * | 2012-03-19 | 2013-09-19 | Hoffmann-La Roche Inc. | Method for administration |
CN102690826B (zh) * | 2012-04-19 | 2014-03-05 | 山西医科大学 | 一种特异性降低人Aurora-A基因表达的shRNA及其应用 |
WO2014024993A1 (ja) * | 2012-08-09 | 2014-02-13 | 国立大学法人京都大学 | ピぺラジン誘導体およびその用途 |
US9603844B2 (en) * | 2012-10-22 | 2017-03-28 | Georgetown University | Compositions and methods for treating mammary tumors |
EP2914256B1 (en) | 2012-11-01 | 2019-07-31 | Aileron Therapeutics, Inc. | Disubstituted amino acids and methods of preparation and use thereof |
CA2895504A1 (en) | 2012-12-20 | 2014-06-26 | Merck Sharp & Dohme Corp. | Substituted imidazopyridines as hdm2 inhibitors |
US11407721B2 (en) | 2013-02-19 | 2022-08-09 | Amgen Inc. | CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer |
EP2961735B1 (en) | 2013-02-28 | 2017-09-27 | Amgen Inc. | A benzoic acid derivative mdm2 inhibitor for the treatment of cancer |
AU2014236812B2 (en) | 2013-03-14 | 2018-03-01 | Amgen Inc. | Heteroaryl acid morpholinone compounds as MDM2 inhibitors for the treatment of cancer |
JOP20200296A1 (ar) | 2013-06-10 | 2017-06-16 | Amgen Inc | عمليات صنع وأشكال بلورية من mdm2 مثبط |
PT3013833T (pt) * | 2013-06-26 | 2019-03-20 | Univ Do Porto | Oxazoloisoindolinonas derivadas de triptofanol: ativadoras de molécula pequena da p53 |
PT3114214T (pt) | 2014-03-04 | 2024-01-03 | Fate Therapeutics Inc | Métodos de reprogramação melhorados e plataformas de cultura celular |
WO2016001376A1 (en) | 2014-07-03 | 2016-01-07 | Boehringer Ingelheim International Gmbh | New spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors |
JP2017533889A (ja) | 2014-09-24 | 2017-11-16 | エルロン・セラピューティクス・インコーポレイテッドAileron Therapeutics,Inc. | ペプチド模倣大環状分子およびその使用 |
CN112972378A (zh) | 2014-09-24 | 2021-06-18 | 艾瑞朗医疗公司 | 拟肽大环化合物及其制剂 |
CN105597090B (zh) * | 2014-11-14 | 2022-08-23 | 中国科学院上海营养与健康研究所 | 一种提高cd4阳性t淋巴细胞存活率和活性的试剂及其应用 |
US11304976B2 (en) | 2015-02-18 | 2022-04-19 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
US11318163B2 (en) | 2015-02-18 | 2022-05-03 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
AU2016221305B2 (en) | 2015-02-18 | 2021-05-27 | Enlivex Therapeutics Rdo Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
US11497767B2 (en) | 2015-02-18 | 2022-11-15 | Enlivex Therapeutics R&D Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
US11596652B2 (en) | 2015-02-18 | 2023-03-07 | Enlivex Therapeutics R&D Ltd | Early apoptotic cells for use in treating sepsis |
US11000548B2 (en) | 2015-02-18 | 2021-05-11 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
EP3294318A4 (en) | 2015-03-20 | 2019-04-03 | Aileron Therapeutics, Inc. | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF |
ES2863500T3 (es) | 2015-04-10 | 2021-10-11 | Capsugel Belgium Nv | Formulaciones lipídicas de acetato de abiraterona |
JP6803339B2 (ja) | 2015-04-21 | 2020-12-23 | エンリヴェックス セラピューティクス リミテッド | 治療用のプールされた血液アポトーシス細胞調製物及びそれらの使用 |
US10023613B2 (en) | 2015-09-10 | 2018-07-17 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles as modulators of MCL-1 |
WO2017060431A1 (en) | 2015-10-09 | 2017-04-13 | Boehringer Ingelheim International Gmbh | Spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors |
JP7263005B2 (ja) | 2015-10-16 | 2023-04-24 | フェイト セラピューティクス,インコーポレイテッド | 基底状態の多能性の誘導及び維持に関するプラットフォーム |
AU2016343682A1 (en) | 2015-10-30 | 2018-06-14 | The Regents Of The University Of California | Methods of generating T-cells from stem cells and immunotherapeutic methods using the T-cells |
JP6884155B2 (ja) | 2016-02-18 | 2021-06-09 | エンリヴェックス セラピューティクス リミテッド | 癌治療のための併用免疫療法及びサイトカイン制御療法 |
UA124972C2 (uk) | 2016-07-29 | 2021-12-22 | Янссен Фармацевтика Нв | Способи лікування раку передміхурової залози |
WO2018055527A1 (en) | 2016-09-20 | 2018-03-29 | Glaxosmithkline Intellectual Property (No.2) Limited | Trpv4 antagonists |
TW201825458A (zh) | 2016-09-20 | 2018-07-16 | 英商葛蘭素史克智慧財產(第二)有限公司 | Trpv4拮抗劑 |
KR20190049865A (ko) | 2016-09-20 | 2019-05-09 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | Trpv4 길항제 |
WO2018185135A1 (en) | 2017-04-05 | 2018-10-11 | Boehringer Ingelheim International Gmbh | Anticancer combination therapy |
WO2019134070A1 (en) * | 2018-01-02 | 2019-07-11 | Rui Jin Hospital, Shanghai Jiao Tong University School Of Medicine | Panda as novel therapeutic |
CN108864113B (zh) * | 2018-08-03 | 2021-08-13 | 南方科技大学 | 一种mdm2-hdac双靶点抑制剂、药物组合物及其制备和用途 |
CN109293630A (zh) * | 2018-11-15 | 2019-02-01 | 山东大学 | 含取代吡唑类化合物及其制备方法与应用 |
CN110643557B (zh) * | 2019-04-23 | 2021-12-31 | 天津科技大学 | 一种基因工程菌的构建及其在高效催化5α-雄烯二酮生产中的应用 |
CN113633642A (zh) * | 2021-08-26 | 2021-11-12 | 山东第一医科大学附属青岛眼科医院(山东省眼科研究所、青岛眼科医院) | Abt-263在制备抑制角膜移植免疫排斥反应的药物中的应用 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09249566A (ja) | 1996-03-19 | 1997-09-22 | Takeda Chem Ind Ltd | ピペリジン化合物含有ケモカイン受容体拮抗剤 |
WO1998016527A1 (en) * | 1996-10-15 | 1998-04-23 | Fujisawa Pharmaceutical Co., Ltd. | Benzoxepine derivatives which promote release of growth hormone |
WO1998051687A1 (en) * | 1997-05-14 | 1998-11-19 | Fujisawa Pharmaceutical Co., Ltd. | Piperidino derivatives which promote growth hormone release |
EP0947494A1 (en) | 1998-03-30 | 1999-10-06 | F. Hoffmann-La Roche Ag | Derivatives of phenoxy acetic acid and phenoxymethyltetrazole having antitumor activity |
SI1077941T1 (sl) * | 1998-05-11 | 2010-01-29 | Novo Nordisk As | Spojine, ki imajo lastnost sproščanja rastnega hormona |
GB9819860D0 (en) | 1998-09-12 | 1998-11-04 | Zeneca Ltd | Chemical compounds |
AR035312A1 (es) * | 1999-01-27 | 2004-05-12 | Wyeth Corp | Compuestos de acido hidroxamico que contienen alquinilo como inhibidores de metaloproteinasa de matriz/tace, composicion farmaceutica que los comprenden y el uso de los mismos para la manufactura de un medicamento |
UA73530C2 (uk) * | 1999-11-10 | 2005-08-15 | Ново Нордіск А/С | Сполука з властивостями вивільнювати гормон росту |
EP2301930B1 (en) * | 2000-06-15 | 2016-01-06 | Merck Sharp & Dohme Corp. | Derivatives of hexahydrobenzofuranone useful for the treatment of (inter alia) auto-immune or inflammatory disorders |
US6403584B1 (en) | 2000-06-22 | 2002-06-11 | Merck & Co., Inc. | Substituted nipecotyl derivatives as inhibitors of cell adhesion |
US20020099035A1 (en) * | 2001-01-24 | 2002-07-25 | Sandanayaka Vincent P. | Method for preparing alpha-sulfonyl hydroxamic acid derivatives |
ES2301717T3 (es) | 2001-12-18 | 2008-07-01 | F. Hoffmann-La Roche Ag | Cis-2,4,5-trifenil-imidazolinas y su utilizacion para el tratamiento de tumores. |
CN1182113C (zh) * | 2002-07-19 | 2004-12-29 | 中国科学院上海有机化学研究所 | 2,5-cis-二取代的吡咯烷衍生物、合成方法及其用途 |
US6916833B2 (en) | 2003-03-13 | 2005-07-12 | Hoffmann-La Roche Inc. | Substituted piperidines |
US7632920B2 (en) * | 2003-04-10 | 2009-12-15 | Schering Corporation | Soluble, stable form of HDM2, crystalline forms thereof and methods of use thereof |
US7132421B2 (en) | 2003-06-17 | 2006-11-07 | Hoffmann-La Roche Inc. | CIS-imidazoles |
US7425638B2 (en) | 2003-06-17 | 2008-09-16 | Hoffmann-La Roche Inc. | Cis-imidazolines |
JP4814228B2 (ja) | 2004-05-18 | 2011-11-16 | エフ.ホフマン−ラ ロシュ アーゲー | 新規cis−イミダゾリン |
PL1966151T3 (pl) | 2005-12-13 | 2012-02-29 | Merck Sharp & Dohme | Policykliczne pochodne indazoli jako inhibitory ERK |
-
2007
- 2007-06-27 US US11/769,030 patent/US7884107B2/en active Active
- 2007-06-27 KR KR1020097001772A patent/KR20090042779A/ko not_active Application Discontinuation
- 2007-06-27 CA CA002656398A patent/CA2656398A1/en not_active Abandoned
- 2007-06-27 MX MX2009000285A patent/MX2009000285A/es unknown
- 2007-06-27 EP EP07796521A patent/EP2035416A1/en not_active Withdrawn
- 2007-06-27 WO PCT/US2007/014958 patent/WO2008005268A1/en active Application Filing
- 2007-06-27 CN CNA2007800306960A patent/CN101595107A/zh active Pending
- 2007-06-27 JP JP2009518257A patent/JP2009542666A/ja active Pending
- 2007-06-27 BR BRPI0713119-4A patent/BRPI0713119A2/pt not_active IP Right Cessation
- 2007-06-27 AU AU2007269836A patent/AU2007269836A1/en not_active Abandoned
- 2007-06-28 AR ARP070102892A patent/AR061726A1/es not_active Application Discontinuation
- 2007-06-29 TW TW096123818A patent/TW200808781A/zh unknown
- 2007-07-02 PE PE2007000844A patent/PE20081238A1/es not_active Application Discontinuation
-
2008
- 2008-12-23 IL IL196152A patent/IL196152A0/en unknown
-
2009
- 2009-01-09 ZA ZA200900204A patent/ZA200900204B/xx unknown
- 2009-01-29 NO NO20090469A patent/NO20090469L/no not_active Application Discontinuation
- 2009-01-30 CO CO09008866A patent/CO6150158A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
AR061726A1 (es) | 2008-09-17 |
MX2009000285A (es) | 2009-06-08 |
KR20090042779A (ko) | 2009-04-30 |
EP2035416A1 (en) | 2009-03-18 |
AU2007269836A1 (en) | 2008-01-10 |
CA2656398A1 (en) | 2008-01-10 |
CO6150158A2 (es) | 2010-04-20 |
IL196152A0 (en) | 2009-09-22 |
JP2009542666A (ja) | 2009-12-03 |
NO20090469L (no) | 2009-03-27 |
CN101595107A (zh) | 2009-12-02 |
WO2008005268A1 (en) | 2008-01-10 |
US7884107B2 (en) | 2011-02-08 |
ZA200900204B (en) | 2010-01-27 |
TW200808781A (en) | 2008-02-16 |
BRPI0713119A2 (pt) | 2012-04-17 |
US20080004287A1 (en) | 2008-01-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20081238A1 (es) | Piperidinas sustituidas como antagonistas de hdm2 | |
PE20090952A1 (es) | Compuestos de pirazol moduladores de raf | |
PE20120693A1 (es) | Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2) | |
PE20080951A1 (es) | DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS | |
PE20110328A1 (es) | Compuestos heterociclicos fusionados como moduladores del receptor de la orexina | |
PE20090482A1 (es) | Derivados heterociclicos como antagonistas del receptor ccr2 | |
PE20080404A1 (es) | Derivados bencil-amino-piperidina como inhibidores de cetp | |
EA200601849A1 (ru) | 4-фениламинохиназолин-6-ил-амиды | |
PE20080344A1 (es) | Compuestos 8-azabiciclo[3.2.1]oct-8-il-1,2,3,4-tetrahidroquinolina sustituidos como inhibidores 11b-hsd1 | |
PE20080677A1 (es) | Inhibidores de pirrolotriazina cinaza | |
PE20081845A1 (es) | Nuevos derivados de aminopirimidina como inhibidores de plk1 | |
PE20061436A1 (es) | Derivados de amida sustituida como inhibidores de proteina quinasa | |
PE20070491A1 (es) | Compuestos derivados de 9-azabiciclo[3.3.1]nonano como inhibidores de la recaptacion de neurotransmisores de monoamina | |
PE20070833A1 (es) | Compuestos de pirimidinil benzotiofeno | |
PE20070490A1 (es) | Compuestos derivados de bencimidazol-2-ona sustituidos con piperidina como agonistas del receptor muscarinico m1 | |
PE20090816A1 (es) | Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3 | |
PE20080925A1 (es) | DERIVADOS DE PIRROLO[2,3-b]PIRIDINA COMO INHIBIDORES DE QUINASA, EN PARTICULAR INHIBIDORES IKK2 (O IKK BETA) | |
PE20091090A1 (es) | Derivados de piperidina como agonistas de receptores muscarinicos | |
PE20091724A1 (es) | Derivados de indol como moduladores del receptor nicotinico de acetilcolina alfa 7 | |
PE20121172A1 (es) | Piperidinas sustituidas con actividad en la hdm2 | |
PE20061096A1 (es) | Derivados de oxiindol como agonistas 5-ht4 | |
PE20120031A1 (es) | Compuestos aril metil benzoquinazolinona como moduladores alostericos positivos del receptor m1 | |
PE20071177A1 (es) | Derivados de 3,5-piridina como inhibidores de renina | |
PE20080275A1 (es) | Derivados de 5h-benzo[4,5]ciclohepta[1,2]piridina como inhibidores de tirosina quinasa | |
DE602005021150D1 (de) | 3-substituierte pyridinderivate als h3-antagonisten |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |